| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9769d7f28716c8f6f189c4154f83e5a5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-13 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D491-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D499-64 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-22 |
| filingDate |
2006-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c17f9ddf6fd34bb37190094a1c65bc79
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29b345ee7aadee7b29de1f79b7a4414a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38cd036dead245ad583d6a005e039738
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0b6b8198d3fe74dbe794658ba1b5e713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce600e969ade8a4ea33e8200157c4ef3 |
| publicationDate |
2011-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2006222312-B8 |
| titleOfInvention |
New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal |
| abstract |
Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin δ and rifaximin ε useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention. |
| priorityDate |
2005-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |